Haruaki Ninomiya Selected Research

Sphingolipidoses (Sphingolipidosis)

11/2010	The effect of N-octyl-β-valienamine on β-glucosidase activity in tissues of normal mice.
1/2010	The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases.
5/2007	Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease.
8/2004	N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruaki Ninomiya Research Topics

Disease

10	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 07/2020 - 06/2004
6	Gaucher Disease (Gaucher's Disease) 11/2010 - 08/2004
5	Hypoxia (Hypoxemia) 01/2022 - 12/2018
4	Myocardial Infarction 01/2022 - 01/2015
4	Ischemia 01/2018 - 06/2005
4	Sphingolipidoses (Sphingolipidosis) 11/2010 - 08/2004
4	Tuberous Sclerosis (Bourneville's Disease) 09/2007 - 06/2002
3	Hyperuricemia 01/2022 - 07/2020
3	Heart Failure 01/2022 - 12/2018
3	Reperfusion Injury 01/2020 - 06/2005
3	Long QT Syndrome 10/2016 - 02/2011
3	Hepatolenticular Degeneration (Wilson's Disease) 05/2011 - 02/2005
3	Inborn Genetic Diseases (Disease, Hereditary) 05/2011 - 02/2005
3	Neoplasms (Cancer) 09/2007 - 06/2002
2	Juvenile gout 06/2022 - 08/2015
2	Gout 01/2021 - 07/2020
2	Long Qt Syndrome 2 11/2016 - 12/2013
2	Atrial Fibrillation 09/2015 - 12/2013
2	Infections 07/2014 - 01/2003
2	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2013 - 08/2011
2	Lung Injury 04/2013 - 04/2007
2	GM1 Gangliosidosis (Gangliosidosis GM1) 03/2013 - 08/2011
2	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 11/2011 - 12/2008
2	Hamartoma 09/2007 - 04/2004
2	Alzheimer Disease (Alzheimer's Disease) 01/2007 - 07/2006
1	Atrial Remodeling 07/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Urolithiasis 01/2022
1	Chronic Renal Insufficiency 01/2021
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020
1	Left Ventricular Dysfunction 01/2018
1	Albuminuria 08/2015
1	Fabry Disease (Fabry's Disease) 07/2014
1	Vesicular Stomatitis 07/2014
1	Essential Hypertension 01/2014
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 09/2013
1	Hemorrhage 04/2013

Drug/Important Bio-Agent (IBA)

8	Uric Acid (Urate)IBA 07/2022 - 01/2012
8	Proteins (Proteins, Gene)FDA Link 12/2018 - 12/2008
7	LipidsIBA 07/2020 - 06/2004
6	Messenger RNA (mRNA)IBA 01/2022 - 06/2004
4	AcidsIBA 08/2011 - 10/2003
4	trans-sodium crocetinate (crocetin)IBA 09/2007 - 06/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2018
3	GalactosidasesIBA 07/2014 - 08/2011
3	CopperIBA 05/2011 - 02/2005
3	Glucosylceramidase (Glucocerebrosidase)IBA 11/2010 - 11/2009
2	UromodulinIBA 06/2022 - 08/2015
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2022 - 10/2019
2	cilnidipineIBA 01/2020 - 01/2012
2	FYX-051IBA 01/2018 - 08/2015
2	Mutant Proteins (Protein, Mutant)IBA 10/2016 - 09/2013
2	CholesterolIBA 01/2016 - 06/2004
2	UbiquitinIBA 09/2015 - 12/2008
2	Proteasome Endopeptidase Complex (Proteasome)IBA 09/2015 - 12/2008
2	purineIBA 08/2015 - 03/2007
2	migalastatIBA 07/2014 - 03/2013
2	Inosine Monophosphate (IMP)IBA 04/2013 - 04/2007
2	AMP Deaminase (Myoadenylate Deaminase)IBA 04/2013 - 04/2007
2	Adenosine Monophosphate (AMP)IBA 04/2013 - 04/2007
2	Cardiac MyosinsIBA 11/2011 - 12/2008
2	Carrier Proteins (Binding Protein)IBA 11/2011 - 12/2008
2	Ceruloplasmin (Ferroxidase)IBA 05/2011 - 01/2009
2	GlucosidasesIBA 11/2010 - 11/2010
2	Tuberous Sclerosis Complex 1 ProteinIBA 09/2007 - 05/2007
2	N-octyl-beta-valienamineIBA 05/2007 - 08/2004
2	beta-GlucosidaseIBA 05/2007 - 08/2004
2	CytokinesIBA 02/2007 - 01/2003
1	InflammasomesIBA 07/2022
1	Doxazosin (Cardura)FDA LinkGeneric 01/2022
1	Conditioned Culture MediaIBA 01/2022
1	XanthineIBA 01/2022
1	HypoxanthineIBA 01/2022
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2022
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2021
1	Febuxostat FDA Link 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2020
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 10/2019
1	Carvedilol (Coreg)FDA LinkGeneric 10/2019
1	Angiotensin Receptor AntagonistsIBA 12/2018
1	Irbesartan FDA LinkGeneric 12/2018
1	Angiotensin IIIBA 12/2018
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018
1	Ether (Diethyl Ether)IBA 11/2016
1	Filipin (Filipin III)IBA 01/2016
1	Xanthine OxidaseIBA 08/2015
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2015
1	Transferrin Receptors (Transferrin Receptor)IBA 07/2014
1	Dystroglycans (Dystroglycan)IBA 07/2014
1	Verapamil (Calan)FDA LinkGeneric 07/2014
1	azelnidipineIBA 01/2014
1	Bepridil (Vascor)FDA Link 12/2013
1	Peroxidase (Myeloperoxidase)IBA 04/2013
1	LigandsIBA 03/2013

Therapy/Procedure

4	Therapeutics 01/2022 - 08/2004
1	Heart Transplantation (Grafting, Heart) 12/2018
1	Transplantation 12/2018
1	Oral Administration 03/2013